These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26805938)

  • 1. Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach.
    Srihari S; Kalimutho M; Lal S; Singla J; Patel D; Simpson PT; Khanna KK; Ragan MA
    Mol Biosyst; 2016 Mar; 12(3):963-72. PubMed ID: 26805938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
    Curtis C; Shah SP; Chin SF; Turashvili G; Rueda OM; Dunning MJ; Speed D; Lynch AG; Samarajiwa S; Yuan Y; Gräf S; Ha G; Haffari G; Bashashati A; Russell R; McKinney S; ; Langerød A; Green A; Provenzano E; Wishart G; Pinder S; Watson P; Markowetz F; Murphy L; Ellis I; Purushotham A; Børresen-Dale AL; Brenton JD; Tavaré S; Caldas C; Aparicio S
    Nature; 2012 Apr; 486(7403):346-52. PubMed ID: 22522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.
    Silva GO; He X; Parker JS; Gatza ML; Carey LA; Hou JP; Moulder SL; Marcom PK; Ma J; Rosen JM; Perou CM
    Breast Cancer Res Treat; 2015 Jul; 152(2):347-56. PubMed ID: 26109346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients.
    Ronowicz A; Janaszak-Jasiecka A; Skokowski J; Madanecki P; Bartoszewski R; Bałut M; Seroczyńska B; Kochan K; Bogdan A; Butkus M; Pęksa R; Ratajska M; Kuźniacka A; Wasąg B; Gucwa M; Krzyżanowski M; Jaśkiewicz J; Jankowski Z; Forsberg L; Ochocka JR; Limon J; Crowley MR; Buckley PG; Messiaen L; Dumanski JP; Piotrowski A
    Hum Mutat; 2015 Nov; 36(11):1088-99. PubMed ID: 26219265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer.
    Kikuchi-Koike R; Nagasaka K; Tsuda H; Ishii Y; Sakamoto M; Kikuchi Y; Fukui S; Miyagawa Y; Hiraike H; Kobayashi T; Kinoshita T; Kanai Y; Shibata T; Imoto I; Inazawa J; Matsubara O; Ayabe T
    BMC Cancer; 2019 May; 19(1):521. PubMed ID: 31146704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of copy number alterations in primary breast tumors of South African patients and their impact on functional cellular pathways.
    Lupicki K; Elifio-Esposito S; Fonseca AS; Weber SH; Sugita B; Langa BC; Pereira SRF; Govender D; Panieri E; Hiss DC; Abdul-Rasool S; Cavalli LR
    Int J Oncol; 2018 Dec; 53(6):2745-2757. PubMed ID: 30320392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
    Bertucci F; Finetti P; Viens P; Birnbaum D
    Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penalized regression elucidates aberration hotspots mediating subtype-specific transcriptional responses in breast cancer.
    Yuan Y; Rueda OM; Curtis C; Markowetz F
    Bioinformatics; 2011 Oct; 27(19):2679-85. PubMed ID: 21804112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short somatic alterations at the site of copy number variation in breast cancer.
    Murakami F; Tsuboi Y; Takahashi Y; Horimoto Y; Mogushi K; Ito T; Emi M; Matsubara D; Shibata T; Saito M; Murakami Y
    Cancer Sci; 2021 Jan; 112(1):444-453. PubMed ID: 32860329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes.
    Dutta B; Pusztai L; Qi Y; André F; Lazar V; Bianchini G; Ueno N; Agarwal R; Wang B; Shiang CY; Hortobagyi GN; Mills GB; Symmans WF; Balázsi G
    Br J Cancer; 2012 Mar; 106(6):1107-16. PubMed ID: 22343619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
    López-Knowles E; Wilkerson PM; Ribas R; Anderson H; Mackay A; Ghazoui Z; Rani A; Osin P; Nerurkar A; Renshaw L; Larionov A; Miller WR; Dixon JM; Reis-Filho JS; Dunbier AK; Martin LA; Dowsett M
    Breast Cancer Res; 2015 Mar; 17(1):35. PubMed ID: 25888249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
    Natrajan R; Weigelt B; Mackay A; Geyer FC; Grigoriadis A; Tan DS; Jones C; Lord CJ; Vatcheva R; Rodriguez-Pinilla SM; Palacios J; Ashworth A; Reis-Filho JS
    Breast Cancer Res Treat; 2010 Jun; 121(3):575-89. PubMed ID: 19688261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sparse regulatory network of copy-number driven gene expression reveals putative breast cancer oncogenes.
    Yuan Y; Curtis C; Caldas C; Markowetz F
    IEEE/ACM Trans Comput Biol Bioinform; 2012; 9(4):947-54. PubMed ID: 21788678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women.
    Loo LW; Wang Y; Flynn EM; Lund MJ; Bowles EJ; Buist DS; Liff JM; Flagg EW; Coates RJ; Eley JW; Hsu L; Porter PL
    Breast Cancer Res Treat; 2011 May; 127(1):297-308. PubMed ID: 21264507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
    Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
    Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inferring causal genomic alterations in breast cancer using gene expression data.
    Tran LM; Zhang B; Zhang Z; Zhang C; Xie T; Lamb JR; Dai H; Schadt EE; Zhu J
    BMC Syst Biol; 2011 Aug; 5():121. PubMed ID: 21806811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.
    Klæstad E; Opdahl S; Engstrøm MJ; Ytterhus B; Wik E; Bofin AM; Valla M
    Breast Cancer Res Treat; 2020 Feb; 180(1):73-86. PubMed ID: 31950385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.
    Cornen S; Guille A; Adélaïde J; Addou-Klouche L; Finetti P; Saade MR; Manai M; Carbuccia N; Bekhouche I; Letessier A; Raynaud S; Charafe-Jauffret E; Jacquemier J; Spicuglia S; de The H; Viens P; Bertucci F; Birnbaum D; Chaffanet M
    PLoS One; 2014; 9(1):e81843. PubMed ID: 24416132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer.
    Liu R; Lv QL; Yu J; Hu L; Zhang LH; Cheng Y; Zhou HH
    Breast Cancer Res Treat; 2015 Jun; 151(3):607-18. PubMed ID: 25981901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.